Scan Results
Daily timeframePart of the healthcare sector, Bayer Aktiengesellschaft (BAYN.DE) is listed under Drug Manufacturers - General. Valued at $37.17B, BAYN.DE is a large-cap name in its sector. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments.
Market Cap
$37.17B
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
7.98
EPS (TTM)
$-2.19
EPS (Fwd)
$4.74
ROE
-6.9%
ROA
3.6%
Cash
$6.66B
Total Debt
$38.89B
Free CF
$7.31B
52W Change
54.1%
Annual Financials
Cash vs Debt
On the balance sheet, BAYN.DE has $6.66B in cash with $38.89B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $7.31B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -6.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $50.74B (2022) to $45.58B (2025), a 10% decline worth watching.
Bayer Aktiengesellschaft carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BAYN.DE.